EGFR and penile cancer: Currently, the role of anti-epidermal growth factor receptor (anti-EGFR) targeted therapy (cetuximab, panitumumab, and dacomitinib) in the treatment of advanced penile cancer is investigational (recommendation, LE: 1b-) as the available literature is still limited (Necchi et al. 2018; Carthon et al. 2014; Brown et al. 2014; Buonerba et al. 2016).